Crosslink Therapeutics
Crosslink Therapeutics reported $5,500,000 raised in an SEC Form D filed on 2026-10-20. State of the filing: Massachusetts.
- Industry
- Pharmaceuticals
- Location
- Massachusetts
About
Crosslink Therapeutics appears in Section 3 of the Raise Track Update of 2026-10-21, which lists new SEC Form D filings. The filing reports $5,500,000 raised and gives Massachusetts as the state. The industry on the filing is Pharmaceuticals. Related persons named on the filing: Ronald Seidel, III (executive officer, director, Boston, Massachusetts); Andrew King (director, Boston, Massachusetts); Lou Tartaglia (director, Boston, Massachusetts); Rodolfo Chaparro (director, Boston, Massachusetts); David Fallace (director, Boston, Massachusetts); Cameron Gallagher (director, Boston, Massachusetts). Filing: https://www.sec.gov/Archives/edgar/data/2067583/000206758326000002/0002067583-26-000002-index.htm
An earlier Form D filed 2025-05-15 reports $4,250,000 sold of $8,000,000. It is not in this issue. The amounts are not combined.
This page is not indexed by search engines yet. A Form D on its own does not name investors or a round type, so the page is promoted once a second source confirms the raise.
Funding history
| Round | Date | Amount | Lead |
|---|---|---|---|
| Form D 2026 | 2026-10-20 | $5.5M |
Sources
Last verified:
- https://www.sec.gov/Archives/edgar/data/2067583/000206758326000002/0002067583-26-000002-index.htm
Type: sec filing. Accessed 2026-10-21.
SEC Form D for Crosslink Therapeutics Inc.. EDGAR filing date 2026-10-20. Signed 2026-10-20. First sale 2026-10-08. Total amount sold $5,500,000 of an offering amount of $5,500,000. 8 investors already invested. Issuer address city is Boston, Massachusetts. Jurisdiction of incorporation is Delaware. Entity type on the form is Corporation. Year of incorporation on the form: 2021. The form does not name the purchasers or a round type. Street addresses are not published. The form describes the securities as an option, warrant, or other right to acquire another security, and the security to be acquired upon exercise. The form spells the first related person Ronald D. Seidel, III. This page uses Ronald Seidel, III, the name in the Raise Track Update. An earlier Form D filed 2025-05-15 reports $4,250,000 sold of $8,000,000. It is not in this issue. The amounts are not combined. - https://buttondown.com/raisetrack/archive/raise-track-update-2026-10-21/
Type: other verified public source. Accessed 2026-10-21.
Raise Track Update for 2026-10-21, Section 3. Lists Crosslink Therapeutics, state MASSACHUSETTS, industry Pharmaceuticals, amount raised $5,500,000.